The teleconference call is under way but not much yet on Vytorin. As for the loss, the drugmaker cited accounting rules related to the purchase of Organon BioSciences. The loss amounted to $2.08 per share for the three months ended Dec. 31, compared with a profit of $182 million, or 12 cents per share, a year earlier. Without the accounting adjustments, Schering-Plough would have had a profit of 27 cents, compared with 24 cents expected by analysts, according to Thomson Financial.

Revenue rose 40 percent to $3.72 billion from $2.65 billion a year ago and exceeding analyst estimates of $3.1 billion, and reported double-digit sales increases in each of its three segments, prescription pharmaceuticals, consumer health care and animal health. Organon was acquired in November for about $14.4 billion in cash.

Among product sales, the Remicade arthritis treatment rose 35 pecent to $455 million and the Nasonex allergy treatment increased 7 percent to $271 million. For all of 2007, Schering-Plough showed a loss of $1.6 billion, or $1.04, compared to a profit of $1.1 billion, or 71 cents, for 2006. Revenue for 2007 rose 20 percent to $12.7 billiion. Here’s the Schering-Plough statement.